SLDBSolid Biosciences Inc.

Nasdaq solidbio.com


$ 8.53 $ 0.09 (1.07 %)    

Thursday, 25-Apr-2024 15:59:50 EDT
QQQ $ 429.78 $ 8.76 (2.08 %)
DIA $ 380.88 $ -3.56 (-0.93 %)
SPY $ 504.47 $ 2.21 (0.44 %)
TLT $ 87.78 $ -0.14 (-0.16 %)
GLD $ 215.92 $ 1.27 (0.59 %)
$ 8.77
$ 8.44
$ 0.00 x 0
$ 0.00 x 0
$ 7.98 - $ 8.56
$ 1.81 - $ 15.05
138,410
na
174.38M
$ 1.16
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-13-2024 12-31-2023 10-K
2 11-08-2023 09-30-2023 10-Q
3 08-14-2023 06-30-2023 10-Q
4 05-11-2023 03-31-2023 10-Q
5 03-23-2023 12-31-2022 10-K
6 11-10-2022 09-30-2022 10-Q
7 08-11-2022 06-30-2022 10-Q
8 04-27-2022 03-31-2022 10-Q
9 03-14-2022 12-31-2021 10-K
10 11-03-2021 09-30-2021 10-Q
11 08-16-2021 06-30-2021 10-Q
12 05-14-2021 03-31-2021 10-Q
13 03-15-2021 12-31-2020 10-K
14 11-05-2020 09-30-2020 10-Q
15 08-06-2020 06-30-2020 10-Q
16 05-07-2020 03-31-2020 10-Q
17 03-12-2020 12-31-2019 10-K
18 11-12-2019 09-30-2019 10-Q
19 08-14-2019 06-30-2019 10-Q
20 05-13-2019 03-31-2019 10-Q
21 03-13-2019 12-31-2018 10-K
22 11-13-2018 09-30-2018 10-Q
23 08-10-2018 06-30-2018 10-Q
24 05-10-2018 03-31-2018 10-Q
25 03-29-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 solid-biosciences-receives-rare-pediatric-disease-designation-from-the-fda-for-duchenne-muscular-dystrophy-gene-therapy-candidate-sgt-003

Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for neuromuscular and card...

 william-blair-initiates-coverage-on-solid-biosciences-with-outperform-rating-announces-price-target-of-40

William Blair analyst Tim Lugo initiates coverage on Solid Biosciences (NASDAQ:SLDB) with a Outperform rating and announces ...

 barclays-maintains-overweight-on-solid-biosciences-raises-price-target-to-21

Barclays analyst Gena Wang maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and raises the price target from $8 t...

 citigroup-initiates-coverage-on-solid-biosciences-with-buy-rating-announces-price-target-of-16

Citigroup analyst David Hoang initiates coverage on Solid Biosciences (NASDAQ:SLDB) with a Buy rating and announces Price Ta...

 blend-labs-reports-q4-results-joins-alta-equipment-despegarcom-and-other-big-stocks-moving-higher-on-friday

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Friday. Shares of Blend Labs, Inc. (NASDAQ: BLN...

 hc-wainwright--co-reiterates-buy-on-solid-biosciences-maintains-16-price-target

HC Wainwright & Co. analyst Arthur He reiterates Solid Biosciences (NASDAQ:SLDB) with a Buy and maintains $16 price target.

 piper-sandler-upgrades-solid-biosciences-to-overweight-raises-price-target-to-20

Piper Sandler analyst Christopher Raymond upgrades Solid Biosciences (NASDAQ:SLDB) from Neutral to Overweight and raises the...

 top-4-health-care-stocks-you-may-want-to-dump-in-february

As of Feb. 15, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as ...

 why-amd-shares-are-trading-lower-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of Advanced Micro Devices, Inc. (NASDAQ: AMD) shares declined 3.8% to $165.49 following fourth-quarter results. AMD rep...

 solid-biosciences-granted-fda-orphan-drug-designation-for-duchenne-muscular-dystrophy-gene-therapy-candidate-sgt-003-patient-dosing-expected-to-begin-mid-to-late-q1-2024

– Patient dosing expected to begin mid-to-late Q1 2024 – CHARLESTOWN, Mass., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Solid Bioscience...

 insiders-buying-solid-biosciences-and-2-other-stocks

Although U.S. stocks closed mixed on Friday, there were a few notable insider trades.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION